Localization and Characterization of Mutations Within the Factor VIII Gene in a Cohort of 212 Patients with Hemophilia A

Author(s):  
J. Schröder ◽  
V. Ivaskevicius ◽  
S. Rost ◽  
A. Müller ◽  
H.-H. Brackmann ◽  
...  
Blood ◽  
1989 ◽  
Vol 74 (3) ◽  
pp. 1045-1051
Author(s):  
M Higuchi ◽  
L Kochhan ◽  
R Schwaab ◽  
H Egli ◽  
HH Brackmann ◽  
...  

Hemophilia A is an X-linked bleeding disorder caused by a deficiency or abnormality of factor VIII, affecting approximately 1 male in 10,000. A subgroup of the patients develops inhibitors against factor VIII during substitution therapy. Because a considerable percentage of all cases is thought to result from de novo mutations, it is likely that many different molecular lesions lead to hemophilia A. In order to understand the molecular basis of this disorder, we examined 160 patients with different clinical features using factor VIII gene probes. We could identify six different deletions and seven nonsense mutations within the factor VIII gene. Family analysis revealed that five of these mutations occurred de novo within two generations; two of them arose in the maternal grandfather and three in the mother. In one of these mothers we could identify a mitotic origin. Mapping of the deletions showed no deletion-prone region within the gene. Furthermore, we could not find any correlation between the particular gene defects and “inhibitor” phenotypes.


2017 ◽  
Vol 28 (5) ◽  
pp. 392-402 ◽  
Author(s):  
Jenny A. Greig ◽  
Qiang Wang ◽  
Amanda L. Reicherter ◽  
Shu-Jen Chen ◽  
Alexandra L. Hanlon ◽  
...  

Blood ◽  
1989 ◽  
Vol 74 (3) ◽  
pp. 1045-1051 ◽  
Author(s):  
M Higuchi ◽  
L Kochhan ◽  
R Schwaab ◽  
H Egli ◽  
HH Brackmann ◽  
...  

Abstract Hemophilia A is an X-linked bleeding disorder caused by a deficiency or abnormality of factor VIII, affecting approximately 1 male in 10,000. A subgroup of the patients develops inhibitors against factor VIII during substitution therapy. Because a considerable percentage of all cases is thought to result from de novo mutations, it is likely that many different molecular lesions lead to hemophilia A. In order to understand the molecular basis of this disorder, we examined 160 patients with different clinical features using factor VIII gene probes. We could identify six different deletions and seven nonsense mutations within the factor VIII gene. Family analysis revealed that five of these mutations occurred de novo within two generations; two of them arose in the maternal grandfather and three in the mother. In one of these mothers we could identify a mitotic origin. Mapping of the deletions showed no deletion-prone region within the gene. Furthermore, we could not find any correlation between the particular gene defects and “inhibitor” phenotypes.


1987 ◽  
Author(s):  
D Lillicrap ◽  
A R Giles ◽  
J J A Holden ◽  
B N White

This study has assessed the relative benefits of restriction fragment length polymorphism (RFLP) linkage and coagulation testing in the diagnosis of carriers of hemophilia A. 221 samples from 55 families have been studied for intragenic and flanking RFLPs. All samples were tested for the Factor VIII intragenic Bell RFLP and for the flanking marker St 14. 83% of obligate carrier females were heterozygous at oneor both of these two polymorphicsites. However, only38% of these women were heterozygous at the intragenic site and might safely be offered prenatal diagnosis using this marker for the hemophilia mutation. Carrier diagnosis was obtained in 52% of 81 potential carriers tested. Diagnosis wasbased on intragenic RFLP information in only 48% of these cases. Genetic diagnosis was possible in 27 atrisk women from families with no prior history of hemophilia. Four of these women were diagnosed as carriers on the basis of a gross Factor VIII gene deletion and the remaining 23 women were identified as non-carriers by the Bell (11) and Stl4 (12) RFLP data. 39 women remained undiagnosed after gene analysis studies. 23 of these women were female relatives of sporadic hemophiliacs and thus RFLP segregation analysis was inappropriate. A further 9 potential carriers were undiagnosed because of homozygosity in key individuals in their families. In 31 potential carriers we have quantitated Factor VIII:C (one stage assay) and vWf:Ag (Laurell and ELISA) and derived probabilities for carrier status. In 3 women there was conflicting genetic and coagulation data. Meanwhile, in 12 undiagnosed women from sporadic families, carrier diagnostic probabilities of > 0.9 were obtained. These studies indicate that optimal carrier detection for hemophilia A requires more intragenic and closely linked RFLPs and the continuance of coagulation testing to assist women from sporadic families.


2010 ◽  
Vol 8 (11) ◽  
pp. 2472-2477 ◽  
Author(s):  
C. J. BOOTH ◽  
M. B. BROOKS ◽  
S. ROCKWELL ◽  
J. W. MURPHY ◽  
H. M. RINDER ◽  
...  

Blood ◽  
2002 ◽  
Vol 100 (9) ◽  
pp. 3432-3432 ◽  
Author(s):  
Federica Riccardi ◽  
Annarita Tagliaferri ◽  
Cesare Manotti ◽  
Corrado Pattacini ◽  
Tauro Maria Neri

Sign in / Sign up

Export Citation Format

Share Document